Introduction: A Life-Saving Breakthrough Under Scrutiny
Spinal Muscular Atrophy (SMA), a rare and devastating genetic disorder, is characterized by the progressive degeneration of motor neurons, leading to severe muscle weakness, respiratory failure, and, in the absence of treatment, early mortality. For years, the diagnosis of SMA was a terminal sentence for thousands of families in India. However, the introduction of Risdiplam—marketed globally as Evrysdi by Roche Pharmaceuticals—offered a transformative shift. As the first at-home, oral treatment for SMA, Risdiplam has been credited with slowing motor degeneration and significantly improving the quality of life for those afflicted.
In a landmark move, the Government of Kerala became the first state in India to provide this life-saving medication free of cost to eligible patients starting in 2022. Yet, what began as a beacon of hope for hundreds of families has recently descended into a firestorm of controversy. The state’s transition from the expensive, branded Evrysdi to a significantly more affordable generic alternative, Natsmart, has pitted desperate parents against public health administrators and medical experts, raising critical questions about the ethics of drug procurement, the efficacy of generic medicine, and the transparency of government healthcare initiatives.
The Chronology of Kerala’s SMA Initiative
The trajectory of Kerala’s SMA program reflects the state’s commitment to public health, but also highlights the immense fiscal pressure of managing rare diseases.
- 2022: Kerala launches a pioneering program to provide Evrysdi free of charge through government hospitals, specifically targeting children under 12. An dedicated SMA clinic is established at the SAT Hospital in Thiruvananthapuram.
- 2025 (October): After extensive deliberations by a technical expert committee, the government decides to shift procurement to Natsmart, a generic version of Risdiplam produced by Natco Pharma, following a historic Delhi High Court ruling that facilitated its market entry.
- 2026 (February): The state government officially authorizes the procurement of Natsmart to replace the expensive branded drug.
- 2026 (Current): The first batch of generic medicine is dispensed at the SAT Hospital, triggering public outcry after parents notice labels on the bottles indicating they were intended for "physician samples/clinical trials."
The Fiscal Burden vs. The Patient Experience
The decision to transition to a generic drug was driven by the crushing financial burden of the branded medication. Under the original model, Evrysdi cost approximately ₹6.3 lakh per bottle (later negotiated to ₹5.4 lakh). With an annual requirement of 2,500 bottles, the state faced a staggering annual financial commitment of ₹23 crore. As the government expanded coverage to include children up to age 25 with genetically confirmed SMA Type 2—backed by a ₹30 crore budget allocation—the sustainability of the program became a primary concern.
In stark contrast, the generic version, Natsmart, is priced at approximately ₹15,900 per bottle. Given that a single bottle lasts only 12 days, the cost of the branded drug could reach ₹60–70 lakh per patient annually. The generic alternative, however, brings that cost down to under ₹5 lakh per year, potentially allowing the state to provide treatment to a vastly larger number of patients within the same budget.
The Parents’ Plea: Safety and Efficacy Concerns
For the families of children currently thriving on Evrysdi, the transition is not merely a budgetary exercise; they perceive it as a threat to their children’s survival. The Cure SMA Foundation of India and various parent advocacy groups have consistently voiced their opposition to the switch.
Their primary arguments center on:
- Lack of Long-Term Data: Parents argue that while Evrysdi has a proven track record, the generic version lacks long-term clinical studies specific to pediatric populations.
- Risk of Regression: There is a deep-seated fear that even a slight variance in the generic formulation could reverse the motor and respiratory progress already achieved by children currently stable on the original medication.
- Transparency: The recent incident involving bottles labeled as "physician samples" has severely eroded trust between the parents and the administration, fueling suspicions that the children are being used as subjects for unverified medication.
The Scientific and Regulatory Defense
Public health experts and the state government have largely dismissed the concerns regarding the efficacy of the generic drug as unscientific. The crux of their defense rests on the regulatory approval provided by the Central Drugs Standard Control Organisation (CDSCO).
The Bioequivalence Debate
A point of contention has been the absence of a conventional human bioequivalence study for Natsmart. However, experts point out that according to the World Health Organization (WHO) guidelines, bioequivalence studies can be waived for certain oral solutions if they are pharmaceutically equivalent and contain the same active ingredient at the same concentration.
Public health advocates argue that:
- Natsmart contains the same molecule (Risdiplam) as the branded version.
- Regulatory bodies have deemed it safe and interchangeable.
- The argument for "bioavailability" is often misunderstood by the public, and in this case, the pharmacological profile is essentially identical.
- Many premier teaching hospitals across India are already utilizing the generic version without reported adverse effects.
Experts assert that in a publicly funded healthcare system, procurement must be guided by regulatory approval and scientific standards, not brand perception. They contend that if the generic were unsafe, it would not have been granted the legal and regulatory clearance to enter the market.
The "Clinical Trial" Labeling Controversy
The most recent flashpoint occurred when parents at the SAT Hospital received bottles labeled "Physician’s sample/for clinical trials." This discovery was quickly weaponized by political opposition, including the CPI(M), to paint the government’s actions as negligent and predatory.
The hospital administration has since clarified that these were not, in fact, experimental drugs. Instead, due to a delay in the government’s formal procurement supply chain, authorities had sourced available stock directly from the manufacturer, Natco, to ensure that no child’s treatment was interrupted. While the intent was to ensure continuity of care, the lack of clear communication to the parents resulted in a major trust deficit. Authorities have acknowledged that the confusion was a communication failure, noting that the labeling issue is entirely distinct from the scientific validity of the generic drug itself.
Implications for Public Health Policy
The situation in Kerala serves as a microcosm for the larger challenge of providing rare disease treatments in developing nations. The "Branded vs. Generic" debate is not merely about cost; it is about the intersection of human rights, medical ethics, and the economics of scarcity.
The Way Forward
To resolve this impasse, the state government faces a dual challenge:
- Restoring Trust: The SAT Hospital must facilitate transparent, science-led dialogues with parent groups. Providing access to existing patient data and regulatory documentation is essential to assuage fears.
- Robust Monitoring: To silence critics, the government should implement a rigorous pharmacovigilance program. By monitoring the children on Natsmart with strict medical oversight and documenting their progress, the state can generate its own local evidence base, which would be the most effective answer to concerns about efficacy.
The goal of public health is to maximize access. If a generic, affordable, and government-approved drug can facilitate the treatment of 100 children instead of 10, the ethical imperative is clear. However, this must be balanced with the psychological and medical peace of mind of the families who have fought for years to secure their children’s health. The Kerala government’s next steps will likely set a national precedent for how India handles the procurement of drugs for rare diseases in the coming decade.
The transition to generic medication is a necessary evolution for a sustainable healthcare system, but it must be handled with empathy, clinical precision, and absolute transparency to ensure that the search for affordability does not come at the cost of the very lives it seeks to save.
